Corporate Finance

Needham is solely focused on growth companies and their investors

Why Needham Corporate Finance?

Needham & Company, LLC recognizes that as a growth company, you require dynamic investment banking services that are unique and practical. Our investment banking group is focused on delivering creative, independent solutions to the growth companies of today and tomorrow. Needham’s expertise extends beyond the United States to various markets globally, such as China, Europe and Israel. Needham’s broad-based investment banking capabilities include public and private equity capital raises and strategic advisory services. A long history of meaningful relationships, deep industry knowledge and focused expertise enables us to provide sound guidance and support in an often turbulent, constantly evolving business environment.

As an employee-owned entrepreneurial firm, Needham is driven by client relationships. We approach each engagement as an opportunity to establish a long lasting partnership that will endure well beyond the immediacy of the transaction. It is this philosophy that has given hundreds of public and private companies worldwide the confidence to rely on Needham for their investment banking needs.

Needham’s investment banking group is committed to companies with market capitalizations less than $5 billion. Our core knowledge and deep domain expertise is concentrated in the following industry verticals:

  • Clean Technology
  • Communications
  • Financial Services
  • Enterprise Infrastructure
  • Healthcare
  • Industrial & Diversified Growth
  • Internet, Digital Media & Consumer
  • Semiconductors & Semiconductor Capital Equipment
  • Software & Services

By serving a focused customer base, we offer a high level of client service and extensive attention from experienced senior professionals and management throughout the entire lifecycle of a transaction.

  • Aeglea (NASDAQ: AGLE) is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

    Aeglea BioTherapeutics, Inc. raised $54.82 million in its upsized initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 481,940 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Aeglea BioTherapeutics, Inc. for general corporate purposes including working capital, product development and operating expenses.

  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies.

    Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency (RF) solutions for the growing CATV infrastructure, small-cell, WiFi, and cellular markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional reliability, performance and integration to deliver a unique competitive advantage to OEMs and ODMs for infrastructure and mobile applications. The Company’s award-winning solutions include line amplifiers, upstream amplifiers, power amplifiers, front-end ICs, front-end modules and other RF components.

    ANADIGICS, Inc. (NASDAQ: ANAD), a world leader in radio frequency (RF) solutions, completed its previously announced sale to II‐VI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components for approximately $78.2 million in cash. Needham & Company acted as the exclusive financial advisor to ANADIGICS, Inc.

  • IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.

    IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.

  • ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

    ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.

  • PMC (NASDAQ: PMCS) is the semiconductor and software solutions innovator transforming networks that connect, move and store big data. Building on a track record of technology leadership, PMC is driving innovation across storage, optical and mobile networks. PMC's highly integrated solutions increase performance and enable next-generation services to accelerate the network transformation.

    PMC-Sierra, Inc., a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC) ("Microsemi"), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, PMC-Sierra's shareholders have received $9.22 in cash and 0.0771 of a share of Microsemi common stock for each share of PMC common stock through an exchange offer. Needham & Company acted as a financial advisor to PMC-Sierra, Inc.

  • Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT™ Phase 3 program in non-dialysis patients commenced in late 2015 and the INNO2VATE™ Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016.

    Akebia Therapeutics, Inc. raised $65.3 million in its follow-on offering at $9.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. offering to fund continued clinical development of vadadustat in patients with anemia secondary to chronic kidney disease (CKD), including to prepare, initiate and conduct its PRO2TECT™ Phase 3 program and to prepare and initiate its planned INNO2VATE™ Phase 3 program, to advance AKB-6899 through Phase 1 development in oncology, and the remainder for working capital and other general corporate purposes.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

    ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C.

    Cempra, Inc. raised $100.0 million in its follow-on offering at $24.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S., subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.

  • Yirendai (NYSE: YRD) is a leading online consumer finance marketplace in China connecting investors and individual borrowers. The Company provides an effective solution to address largely underserved investor and individual borrower demand in China through an online platform that automates key aspects of its operations to efficiently match borrowers with investors and execute loan transactions. Yirendai deploys a proprietary risk management system, which enables the Company to effectively assess the creditworthiness of borrowers, appropriately price the risks associated with borrowers, and offer quality loan investment opportunities to investors. Yirendai's online marketplace provides borrowers with quick and convenient access to consumer credit at competitive prices and investors with easy and quick access to an alternative asset class with attractive returns.

    Yirendai Ltd. raised $75 million in its initial public offering at $10.00 per share. Needham acted as a passive bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Yirendai Ltd. for general corporate purposes, which may include investment in product development, sales and marketing activities, technology infrastructure, capital expenditures, improvement of corporate facilities and other general and administrative matters. The company may also use a portion of these proceeds for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business.

  • Pertino is a new way to WAN for the mobile and cloud era—secure, software-defined and delivered as a service. Mobile and cloud technologies are transforming IT, resulting in a hybrid IT model where distributed workforces and workloads are reliant on the Internet. Our Cloud Network Engine platform enables enterprises to build and manage private cloud networks that overlay the public Internet, securely connecting people, devices and resources anywhere. With AppScape, our network services app store, Pertino cloud networks can be extended with enterprise-level visibility, security and control services. This modern approach to networking combines the power and pervasiveness of the cloud with SDN and virtualization technologies to eliminate cost and complexity. Finally, a WAN that is cloud-agile and works the way organizations work today, without hardware, hassles, or high costs. Founded in 2011, Pertino is venture funded by premier firms and headquartered in Los Gatos, California.

    Pertino, a privately-held Silicon Valley company that has pioneered the use of software-defined networking to deliver cloud-based networks as-a-service for enterprise and SMB customers worldwide, completed its previously announced sale to Cradlepoint, the global leader in software-defined 4G LTE network solutions for enterprises. The terms of the transaction were not disclosed. Needham & Company acted as the exclusive financial advisor to Pertino.

  • The Chinese consortium of investors was led by SummitView Capital and includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management. Summitview Capital is a private equity firm specializing in buyouts. It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry. Summitview Capital is based in Shanghai China, with an additional office in Changzhou, China.

    A Chinese consortium of investors led by SummitView Capital and that includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management announced that it has completed the acquisition of Integrated Silicon Solution, Inc. (NASDAQ: ISSI), a global fabless semiconductor company, for a net purchase price of $782.6 million in cash. Needham & Company acted as a financial advisor to the Chinese consortium.

  • Inphi Corporation (NYSE: IPHI) is a leading provider of high-speed, mixed-signal semiconductor solutions for the communications, computing and data center markets. Inphi’s end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi’s solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi’s solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms.

    Inphi Corporation issued $230.0 million principal amount of Convertible Senior Notes due 2020. The size of the offering was increased to $200.0 from the previously announced $150.0 million aggregate principal amount. Prior to June 1, 2020, the notes will be convertible only under certain circumstances and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The initial conversion rate for the notes will be 24.8988 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $40.16 per share, and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 35.0% over the last reported sale price of $29.75 per share of Inphi's common stock on The New York Stock Exchange on December 2, 2015. Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction.

  • Instructure, Inc. (NYSE: INST) is a leading software-as-a-service (SaaS) technology company that makes software that makes people smarter. With a vision to help maximize the potential of people through technology, Instructure created Canvas and Bridge to enable organizations everywhere to easily develop, deliver and manage engaging face-to-face and online learning experiences. To date, Instructure has connected millions of teachers and learners at more than 1,800 educational institutions and corporations throughout the world.

    Instructure, Inc. raised $81.0 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 660,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Instructure, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development activities, general and administrative matters and capital expenditures. They may also use a portion of the net proceeds from this offering for acquisitions of, or investments in, technologies, solutions or businesses that complement the business.

  • Xoom Corporation (NASDAQ: XOOM) is a leading digital money transfer provider that enables consumers to send money, pay bills and send mobile reloads to family and friends around the world in a secure, fast and cost-effective way, using their mobile phone, tablet or computer. During the 12 months ended March 31, 2015, Xoom’s more than 1.3 million active customers sent approximately $7.0 billion with Xoom.

    Xoom Corporation, a digital money transfer provider, completed its previously announced sale to PayPal, Inc. (NASDAQ: PYPL), a provider of a worldwide online payments system. In accordance with the terms of the acquisition agreement announced on July 1, 2015, PayPal acquired all of the outstanding shares of Xoom for $25 per share in cash. Xoom will operate as a separate service within PayPal. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Xoom Corporation as part of its services.

  • Xtera Communications, Inc. (NASDAQ: XCOM) is a leading provider of high-capacity, cost-effective optical transport solutions, supporting the high growth in global demand for bandwidth. Xtera sells solutions to telecommunications service providers, content service providers, enterprises and government entities worldwide. Xtera’s proprietary Wise RamanTM optical amplification technology leads to capacity and reach performance advantages over competitive products. Xtera’s solutions enable cost-effective capacity to meet customers’ bandwidth requirements of today and to support their increasing bandwidth demand fueled by the development of data centers and related cloud-based services.

    XTERA Communications Inc. raised $25.0 million in its offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by XTERA Communications Inc. for working capital and other general corporate purposes, including to finance our expected growth, develop new products or fund capital expenditures. The Company may also use a portion of the net proceeds to repay borrowings under its credit facility or term loan, or to expand its existing business through acquisitions of other businesses, products or technologies.

  • LendingTree, Inc. (NASDAQ: TREE) operates a leading online loan marketplace and provides consumers with an array of online tools and information to help them find the best loans for their needs. The Company's online marketplace connects consumers with multiple lenders that compete for their business, empowering consumers as they comparison-shop across a full suite of loans and credit-based offerings. The Company provides access to lenders offering home loans, home equity loans/lines of credit, reverse mortgages, personal loans, auto loans, small business loans, credit cards, student loans and more.

    LendingTree, Inc. raised $112.41 million in its follow-on offering at $115.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 127,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by LendingTree, Inc. for general corporate purposes, including but not limited to, working capital and potential acquisitions.

  • iboss Cybersecurity defends today’s large, distributed organizations against targeted cyber threats which lead to data loss, with the iboss next-gen Secure Web Gateway Platform, leveraging innovative cloud architecture and patented advanced threat defense technologies. iboss advanced solutions deliver unparalleled visibility across all inbound/outbound data channels, and include security weapons that reveal blind spots, detect breaches and minimize the consequences of data exfiltration. With leading threat protection and unsurpassed usability, iboss is trusted by thousands of organizations and millions of users.

    iBoss, Inc. raised $35.0 million in Series A funds from Goldman Sachs’ Private Capital Investing group. The new financing will allow iboss to aggressively develop groundbreaking technology, including the rollout of its next-generation cloud platform, while continuing to expand globally. Needham acted as the sole placement agent for this transaction.

  • Adesto Technologies Corporation (NASDAQ: IOTS) offers the world’s lowest power memory solutions unleashing innovation for a new class of connected applications and previously unimagined devices. The company has designed and built a portfolio of innovative products, including Fusion Serial Flash, DataFlash® and Mavriq™ serial memory. Adesto holds more than 100 patents with dozens more in process and is working with visionary companies across various industries to deploy its technology to the market.

    Adesto Technologies Corporation raised $25.0 million in its initial public offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Adesto Technologies Corporation use the net proceeds from this offering for working capital and other general corporate purposes, to acquire or invest in complementary businesses, products, services, technologies or other assets, and for potential pay down of a $15.0 million term loan facility.

  • Intronis provides data protection solutions for small businesses, delivered exclusively through the IT channel. The Intronis ECHOplatform securely protects physical and virtual data with native support for physical imaging,VMware, Hyper-V, Exchange, and SQL, all through a re-brandable central management console that integrates with major RMM and PSA tools. With Intronis' fixed-fee storage pricing per SMB account, IT service providers are able to streamline their pricing strategy and simplify their account management.

    Intronis, Inc. (NASDAQ: SWTX), a leader in providing data protection solutions to managed service providers (MSPs), a fast-growing channel delivering IT services to small and medium-sized businesses, completed its previously announced sale to Barracuda Networks, Inc. (NYSE: CUDA), a provider of cloud-connected security and storage solutions that simplify IT, in an all cash transaction. Needham & Company acted as a financial advisor to Intronis, Inc..

  • Netsertive’s digital marketing intelligence platform empowers brands and local businesses to work together to win local customers. The company’s two complementary solutions, MarketWise™ for Brands and StreetWise™ for Local Businesses, enable cooperative marketing and resource sharing between brands and their local business partners. Both are powered by Netsertive's proprietary learning engine, which combines the company's deep industry experience with the collective intelligence of its extensive network of automotive, IT technology, major appliance, furniture, consumer electronics and healthcare clients to deliver unprecedented campaign speed, performance and value. An award-winning marketing technology company and Google Premier SMB Partner, Netsertive drives local marketing success from campaign enablement through scaled, local execution. Additionally, Netsertive helps brands with their co-op marketing to ensure localized brand compliance, seamless campaign execution and reimbursement tracking for local partners. Founded in 2009 and based in Research Triangle Park, North Carolina, the company has a history of rapid growth, a world-class team and the strength of venture capital funding from top firms RRE Ventures, Harbert Venture Partners, River Cities Capital Funds and Greycroft Partners. Netsertive was named 2014 Software Company of the Year by North Carolina Technology Association and was named among Inc. Magazine’s 500 fastest-growing private companies three years in a row.

    Netsertive raised $15 million in Series C growth financing. River Cities Capital Funds led the round and will be joined by existing investors. The new round will fuel Netsertive’s acceleration in the digital marketing technology arena, as it continues to add major brands for its MarketWise™ solution and local businesses for its StreetWise™ solution. Needham & Company served as exclusive placement agent on this transaction.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases.

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) raised $126.8 million in its follow-on offering at $39.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. for product and commercial development, manufacturing, any business development activities and for general corporate purposes.

  • Dot Hill Systems Corp. (NASDAQ: HILL) solves today's storage workload challenges created by the Internet of Things and third platform technologies leveraging its proprietary AssuredSAN family of hybrid storage solutions with RealStor, the next generation real-time storage operating system. In today's interconnected world, Dot Hill storage solutions support people accessing information, and machines collecting sensor data, all in real time. Dot Hill's solutions combine innovative intelligent software with the industry's most flexible and extensive hardware platform and simplified management to deliver best-in-class solutions. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in the United States, Europe, and Asia.

    Dot Hill Systems Corp. (NASDAQ: HILL), a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Seagate Technology plc (NASDAQ: STX), a world leader in storage solutionsin an all cash transaction. Needham & Company acted as a financial advisor to Dot Hill Systems and provided a fairness opinion to its Board of Directors as part of its services.

  • Medgenics, Inc. (NASDAQ: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases.

    Medgenics, Inc. raised $46.01 million in its follow-on offering at $6.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 923,250 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. for for product development activities, including (a) the development of technologies acquired in the previously announced acquisition of neuroFix, LLC, (b) patent maintenance fees and intellectual property support, (c) licensing and research collaborations and (d) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses and making certain payments in connection with the acquisition of neuroFix, LLC, including an expected $2.8 million payment to satisfy a specific corporate milestone payment to the former stockholders of neuroFix, LLC.

  • Ikanos Communications, Inc. (NASDAQ: IKAN) is a leading provider of advanced broadband semiconductor and software products for the connected home. The company’s broadband DSL, communications processors and other offerings power access infrastructure and customer premises equipment for many of the world’s leading network equipment manufacturers and telecommunications service providers.

    Ikanos Communications, Inc. (NASDAQ: IKAN), a high performance broadband networking semiconductor and software provider enabling both central office and home gateway solutions, completed its previously announced sale to Qualcomm Incorporated (NASDAQ: QCOM), a world leader in 3G, 4G and next-generation wireless technologies. Pursuant to the agreement, Qualcomm Atheros, through a wholly-owned subsidiary, acquired all of the issued and outstanding shares of common stock of Ikanos for $2.75 per share in cash, and assumed all outstanding indebtedness at the closing of the transaction. Needham & Company acted as a financial advisor to Ikanos and provided a fairness opinion to the Board of Directors of Ikanos as part of its services. .

  • 2U, Inc. (NASDAQ: TWOU) partners with leading colleges and universities to deliver the world's best online degree programs so students everywhere can reach their full potential. Our Platform, a fusion of cloud-based software-as-a-service technology and technology-enabled services, provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate students globally.

    2U, Inc. (NASDAQ: TWOU) raised $136.9 million in its follow-on offering at $34.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 525,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by 2U, Inc. for general corporate purposes, including expenditures for program marketing, sales, technology, and content development, in connection with new program launches and growing existing programs.

  • Q2 Holdings, Inc. (NASDAQ: QTWO) is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

    Q2 Holdings, Inc. (NASDAQ: QTWO) raised $111.41 million in its follow-on offering at $25.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 569,850 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Q2 Holdings for general corporate purposes and working capital, including to finance their expected growth, develop new technologies, fund capital expenditures, or expand their existing business through investments in or acquisitions of other businesses or technologies.

  • Paylocity Holding Corporation (NASDAQ: PCTY) is a provider of cloud-based payroll and human capital management, or HCM, software solutions for medium-sized organizations. Paylocity's comprehensive and easy-to-use solutions enable its clients to manage their workforces more effectively. Paylocity's solutions help drive strategic human capital decision-making and improve employee engagement by enhancing the human resource, payroll and finance capabilities of its clients.

    Paylocity Holding Corporation (NASDAQ: PCTY) raised $128.0 million in its follow-on offering at $29.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 561,000 shares of common stock at the follow-on offering price to cover over-allotments. The shares of common stock offered by this prospectus are being registered for the account of the selling stockholders named in the prospectus. As a result, all proceeds from the sales of the common stock will go to the selling stockholders and Paylocity will not receive any proceeds from the resale of the common stock by the selling stockholders.

  • Nabriva Therapeutics AG (NASDAQ: NBRV) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

    Nabriva Therapeutics AG (NASDAQ: NBRV) raised $106.1 million in its initial public offering at $10.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,350,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nabriva to complete the clinical development of lefamulin for CABP, to submit applications for marketing approval for lefamulin for CABP in both the United States and Europe, to pursue the clinical development of lefamulin for additional indications, for earlier stage research and development activities and for working capital and other general corporate purposes.

  • Synacor (NASDAQ:SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises. We deliver modern, multiscreen experiences and advertising to their consumers that require scale, actionable data and sophisticated implementation.

    Synacor Inc. (NASDAQ:SYNC), the trusted multiscreen technology and monetization partner for video, internet and communications providers, device manufacturers, and enterprises, announced that it has completed the acquisition of Zimbra, Inc., a global leader in open source email, calendaring, and collaboration software, for a net purchase price of $24.5 million, with Synacor paying $17.3M in cash, issuing 3M shares, 0.6M warrants priced at $3.00 per share, and paying up to $2M in earn-outs over the next 18 months. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Synacor as part of its services.

  • Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

    Trevena, Inc. (NASDAQ: TRVN) raised $72.9 million in its follow-on offering at $9.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 975,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with its existing cash and investments will be used by Trevena, Inc. to complete Phase 3 development, submit a new drug application, and begin launch preparations for TRV130; to complete its Phase 2b BLAST-AHF study for TRV027; to complete initial Phase 1 studies for TRV250; to continue drug discovery in new therapy areas; and for working capital and general corporate purposes. Needham has now been part of three transactions for Trevena, including its initial public offering in February 2014.

  • Seattle Genetics, Inc. (NASDAQ: SGEN) is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.

    Seattle Genetics, Inc. (NASDAQ: SGEN) raised $552.0 million in its follow-on offering at $41.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,756,097 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Seattle Genetics to fund the ongoing commercialization of ADCETRIS in the United States and Canada, to fund research and development efforts designed to further expand the ADCETRIS label and to advance its pipeline of product candidates, as well as for general corporate purposes, including working capital. The Company may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property. This is the fourth transaction for Seattle Genetics where Needham has been part of the deal team since 2008.

  • Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox’s lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. AQX-1125 has demonstrated preliminary safety and favorable drug properties in multiple preclinical studies and clinical trials. The Firm is currently developing AQX-1125 as an oral, once daily treatment in bladder pain syndrome/interstitial cystitis (BPS/IC). In addition, it is exploring AQX-1125 for atopic dermatitis (AD) in its ongoing Kinship Phase 2 trial. For AQX-1125, the Company retains full worldwide rights and holds patents with terms through at least 2024. Aquinox uses a proprietary screening approach to discover new drug candidates that selectively target SHIP1 to modulate activated immune cells while minimizing their toxicity to normal cells. The Company’s intellectual property covers SHIP1 as a target, the C2 binding domain for screening and the composition of matter for its compounds. Aquinox has an extensive chemical library and several candidate lead compounds that target SHIP1. These compounds have both similar and distinct properties from AQX-1125. The Company believes AQX-1125 is the only SHIP1 activator currently in clinical trials and that no other SHIP1 activator has to date reported data from clinical trials or received marketing approval as a treatment for disease in humans.

    Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) raised $98.04 million in its follow-on offering at $15.50 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals for the clinical development of AGX-1125 in BPS/IC, for research, development and manufacturing of product candidates, and for other general corporate purposes.

  • Autonet Mobile Inc. is a world leading application and service provider for cars. Founded in 2005, Autonet Mobile was the first to deliver in-vehicle Wi-Fi with OE compatibility along with new technologies that support applications that allow owners to access their car from their phones to new forms of security.

    Autonet Mobile, a Santa Rosa company that develops devices and software to connect cars to the Internet, has sold its technology to Michigan auto parts giant Lear Corporation (NYSE: LEA). As part of the deal, Lear hired an undisclosed number of Autonet Mobile’s engineering and research and development workers. As part of the agreement announced this week, Lear acquired technology that uses cellular networks to connect on-board vehicle systems with cloud-based applications. Financial terms were not disclosed. Autonet Mobile will continue to use the technology it sold to Lear to support programs with existing customers and to develop new products for the automotive aftermarket, under a license agreement. Needham & Company acted as a financial advisor to Autonet Mobile, Inc..

  • Corium International, Inc. (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience in advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders.

    Corium International, Inc. (NASDAQ: CORI) raised $52.0 million in its follow-on offering at $13.00 per share. Needham acted as lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Corium International for general corporate purposes, which may include funding research and development, increasing working capital, acquisitions or investments in businesses, products or technologies that are complementary to Corium’s own businesses and capital expenditures.

  • Dermira, Inc. (NASDAQ: DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $111.3 million in its follow-on offering at $21.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all product candidates, working capital, capital expenditures and other general corporate purposes.

  • Selectica, Inc. (NASDAQ: SLTC) provides a platform for enterprises worldwide to create, manage, and optimize business relationships with contracts at the core. Selectica helps global companies actively manage their contracts throughout the sales, procurement, and legal life cycles. Selectica's contract management solutions drive business value by assisting organizations in managing contracts profitably, effectively accelerating revenue opportunities, and minimizing risk through compliance. Through IASTA, a Selectica company, we provide leading supply management and spend management solutions, dedicated to empowering sourcing and purchasing professionals. Our blend of acclaimed software and services focus on improving spend analysis, procurement intelligence, sourcing, and supplier life cycle management. Our solutions play a critical role in optimizing business relationships by enhancing supply base insights, improving supplier collaboration and reducing the supply chain risks vital to today's globally-minded enterprise. Selectica also provides a powerful configuration engine, enabling Fortune 500 companies to accelerate revenue by facilitating the optimization of the right combination of products, services, and price.

    Selectica, Inc. (NASDAQ: SLTC) announced that it has completed the acquisition of b-pack, a global leader in purchase-to-pay (P2P) software and services, for approximately $12.33 million in cash and stock. Needham & Company acted as a financial advisor to Selectica, Inc.

  • Genocea Biosciences, Inc. (NASDAQ: GNCA) is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

    Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $50.1 million in its follow-on offering at $13.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences to fund the clinical development of GEN-003 and GEN-004, continue investment in new research programs, and the balance for other general corporate purposes.

  • Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

    Cara Therapeutics, Inc. (NASDAQ: CARA) raised $80.5 million in its follow-on offering at $18.60 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 564,516 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cara Therapeutics to conduct planned clinical trials of I.V. CR845 and Oral CR845, to fund the research and development of preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes.

  • Intel Corporation (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world’s computing devices. Headquartered in Santa Clara, Calif., Intel today has more than 100,000 employees in 63 countries and serves customers in more than 120 countries. Intel today designs and manufactures a variety of essential technologies, including microprocessors and chipsets and the additional hardware, software, and related services that together serve as the foundation for many of the world’s computing devices. Over the last decade, Intel has evolved from a company that largely serves the PC industry, to a company that increasingly provides the vital intelligence inside all things computing. In fact, one-third of Intel's revenue is associated with products beyond the PC. Hardware and software products by Intel and subsidiaries such as McAfee, power the majority of the world’s data centers, connect hundreds of millions of cellular handsets and help secure and protect computers, mobile devices and corporate and government IT systems. Intel technologies are also inside intelligent systems, such as in automobiles, automated factories and medical devices.

    Intel Corporation (NASDAQ: INTC) issued $7.0 billion principal amount of Convertible Senior Unsecured Notes to finance part of its $16.7 billion takeover of Altera Corp. Needham & Company acted as a co-manager for this transaction.

  • Xactly Corporation (NYSE:XTLY) is a leading provider of enterprise-class, cloud-based, incentive compensation solutions for employee and sales performance management. They address a critical business need: To incentivize employees and align their behaviors with company goals. Xactly's products allow organizations to make more strategic decisions, increase employee performance, improve margins, and mitigate risk. Our core values are key to our success, and each day we’re committed to upholding them by delivering the best we can to their customers.

    Xactly Corporation raised $67.4 million in its initial public offering at $8.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,055,625 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Xactly Corporation for for working capital and other general corporate purposes. The Company also may use a portion of the net proceeds to acquire or invest in complementary businesses, products, services, technologies or other assets.

  • Avid Technology, Inc. (NASDAQ: AVID) delivers the industry's most open, innovative and comprehensive media platform connecting content creation with collaboration, asset protection, distribution and consumption for the most listened to, most watched and most loved media in the world—from the most prestigious and award-winning feature films, music recordings, and television shows, to live concerts and news broadcasts. Industry leading solutions include Pro Tools®, Media Composer®, ISIS®, Interplay®, and Sibelius®.

    Avid Technology, Inc. (Nasdaq: AVID) announced that it has completed the acquisition of Orad Hi-Tec Systems Ltd., a Frankfurt stock exchange-listed public company with its headquarters in Kfar Saba, Israel, for €5.67 per share in an all-cash transaction. Orad is a leading provider of state-of-the-art 3D real-time graphics, video servers and related asset management solutions. The acquisition is consistent with Avid’s stated growth strategy and Avid believes it will continue to deliver on the company’s Avid Everywhere vision, by adding key content creation and media management solutions to the Avid MediaCentral Platform, the industry's most open, innovative and comprehensive media platform. Needham & Company acted as a financial advisor to Avid Technology, Inc.

  • NeoPhotonics Corporation (NASDAQ: NPTN) is a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks. The Company’s products enable cost-effective, high-speed data transmission and efficient allocation of bandwidth over communications networks. NeoPhotonics maintains headquarters in San Jose, California and ISO 9001:2000 certified engineering and manufacturing facilities in Silicon Valley (USA), Japan and China.

    NeoPhotonics Corporation raised $49.8 million in its follow-on offering at $7.25 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 895,655 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by NeoPhotonics Corporation for working capital, to continue to expand their existing business and general corporate purposes.

  • Auris Medical Holding AG (NASDAQ: EARS) is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.

    Auris Medical Holding AG raised $25.1 million in its follow-on offering at $4.75 per share. Needham acted as the joint-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Auris Medical Holding AG to fund research and development expenses for AM-111, for early stage programs, working capital and other general corporate purposes.

  • Camtek Ltd. (NASDAQ: CAMT and TASE: CAMT), provides automated and technologically advanced solutions dedicated to enhancing production processes, increasing products yield and reliability, enabling and supporting customer's latest technologies in the Semiconductors, Printed Circuit Boards (PCB) and IC Substrates industries.

    Camtek, Ltd. raised $13.3 million in its follow-on offering at $2.85 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters exercised their option to purchase an additional 355,982 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Camtek, Ltd. for general corporate purposes.

  • Collegium Pharmaceuticals, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceuticals, Inc. raised $80.4 million in its initial public offering at $12.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 870,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Collegium Pharmaceuticals for the development of commercial infrastructure to launch Xtampza, to fund research and development efforts of additional product candidates, and to fund working capital and general corporate purposes.

  • N-Trig Ltd. is an Israel-technology company started in 1999 that owns more than 100 patents related to digital pens and related technology that helps enable customers to use natural handwriting for input on touch screens. Its technology has been used in dozens of consumer products from Dell, Lenovo, HP, Fujitsu, Sharp, Toshiba and other major OEMs. In 2014, an N-Trig pen became part of Microsoft’s Surface Pro 3 package.

    N-Trig Ltd, a leading innovator in digital pen technology, completed its previously announced sale of the Surface 3 Pen technology specifically and related assets, not the company as a whole to Microsoft Corporation (NASDAQ: MSFT), a multinational technology company that develops, manufactures, licenses, supports and sells computer software, consumer electronics and personal computers and services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to N-trig Ltd.

  • Vitesse (NASDAQ: VTSS) designs a diverse portfolio of high-performance semiconductors, application software, and integrated turnkey systems solutions for Carrier, Enterprise and Internet of Things (IoT) networks worldwide. Vitesse products enable the fastest-growing network infrastructure markets including Mobile Access/IP Edge, Cloud Access and Industrial-IoT Networking.

    Vitesse Semiconductor Corporation (NASDAQ: VTSS), designer of a diverse portfolio of high-performance semiconductors, application software, and integrated turnkey systems solutions for carrier, enterprise and Internet of Things (IoT) networks worldwide, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, each outstanding share of Vitesse (other than shares directly owned by Vitesse and its subsidiaries, Microsemi or LLIU100 Acquisition Corp. and shares held by stockholders that are entitled to and properly demand appraisal of such shares under Delaware law) was converted into the right to receive $5.28 per share in cash, without interest and less any applicable withholding taxes, the same price that was paid in the tender offer. Needham acted as a financial advisor to Vitesse Semiconductor Corporation.

  • SCYNEXIS, Inc. (Nasdaq:SCYX) is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans.

    SCYNEXIS, Inc. (Nasdaq:SCYX) raised $41.4 million in its follow-on offering at $7.70 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 701,298 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by SCYNEXIS, Inc. for working capital, capital expenditures and other general corporate purposes, including preclinical and clinical costs associated with the IV formulation of SCY-078, clinical costs associated with the completion of an ongoing Phase 2 study of oral SCY-078 and the initiation of a study that includes both IV and oral SCY-078.

  • Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) raised $69.0 million in its follow-on offering at $8.25 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,090,909 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. to continue clinical development of AKB-6548 in patients with anemia secondary to chronic kidney disease, including the preparation for and initiation of Phase 3 trials, to advance its preclinical candidate, AKB-6899, through Phase 1 development in oncology, and to increase working capital, as well as for other general corporate purposes.

  • Pernix Therapeutics Holdings, Inc., is a specialty pharmaceutical company, that develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company's product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women's health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.

    Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) issued $130.0 million principal amount of the Company's 4.25% Convertible Senior Notes due 2021Convertible Senior Notes due 2016. The size of the offering was increased from the previously announced aggregate principal amount of $120 million. The notes will pay interest semi-annually at a rate of 4.25% per annum and will mature on April 1, 2021, unless redeemed, repurchased or converted in accordance with their terms prior to such date. The notes will have an initial conversion rate, subject to adjustment, of 87.2030 shares of the Company’s common stock per $1,000 principal amount of the notes, representing a conversion price of approximately $11.47 per share of the Company’s common stock, based on the last reported sale price of $8.34 per share of the Company’s common stock on April 16, 2015. Needham & Company acted as a co-manager for this transaction. Pernix Therapeutics expects to use $80.9 million of the gross proceeds from the offering to finance the cash consideration portion of the consideration necessary to consummate its previously announced acquisition of the Zohydro® ER franchise, approximately $8.3 million to pay fees and expenses related to such acquisition and the offering, up to $2.2 million to pay the consent fee related to the Company’s previously announced consent solicitation of its 12.00% senior secured notes due 2020 and the remainder for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.

  • Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial portfolio is comprised of a long-acting echinocandin antifungal product candidate, CD101 IV, and CD101 topical, for the treatment of serious fungal infections. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California.

    Cidara Therapeutics raised $76.8 million in its upsized initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Cidara Therapeutics for general corporate purposes including working capital, product development and operating expenses.

  • Cradlepoint is the global leader in cloud-managed 4G LTE networking solutions, providing industry-leading WWAN and Security solutions to distributed enterprises. Specializing in Business Continuity, M2M/IoT applications, Application Specific or Parallel Networking and Transportation networking, Cradlepoint's award-winning solutions are purpose built for PCI-compliant networks. Cradlepoint was the first to pioneer and fully enable high-speed LTE solutions to maximize the potential of the cloud for businesses worldwide. Cradlepoint is a privately held company in Boise, Idaho.

    Cradlepoint completed the pricing of a Series B round of $48 million in growth equity funding. Needham & Company served as sole placement agent on this transaction. The proceeds will be used to accelerate Cradlepoint’s international expansion and development of cloud-managed Wireless Wide Area Networks (WWAN) and security solutions.

  • Dyax Corp. is a biopharmaceutical company focused on: Hereditary Angioedema and Other Plasma-Kallikrein-Mediated (PKM)Disorders. It develops and commercializes treatments for hereditary angioedema and Dyax Corp. is working to identify additional disorders that are mediated by plasma kallikrein.

    Dyax Corp. (NASDAQ: DYAX) raised $229.8 million in its follow-on offering at $27.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,110,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dyax Corp. for to develop and, if approved, commercialize DX-2930 worldwide for the prophylactic treatment of hereditary angioedema, for research and development of product candidates to address additional plasma-kallikrein-mediated (PKM) disorders and other orphan diseases outside the PKM pathway, to prepay all of the debt outstanding under the loan agreement with LFRP Investors, L.P., an affiliate of HealthCare Royalty Partners, and for general corporate purposes.

  • Nova Measuring Instrument Ltd. delivers continuous innovation by providing advanced optical metrology solutions for the semiconductor manufacturing industry. Deployed with the world's largest integrated-circuit manufacturers, Nova's products deliver state-of-the-art, high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle. Nova's product portfolio, which combines high-precision hardware and cutting-edge software, supports the development and production of the most advanced devices in today's high-end semiconductor market. Nova's technical innovation and market leadership enable customers to improve process performance, enhance products' yields and accelerate time to market. Nova acts as a partner to semiconductor manufacturers from its offices around the world.

    Nova Measuring Instrument Ltd. (NASDAQ: NVMI) announced that it has completed the acquisition of ReVera Incorporated, a leading provider of materials metrology solutions for complex, multi-layer film stacks for advanced node semiconductor manufacturing for a net purchase price of $46.5 million in cash. Needham & Company acted as a financial advisor as part of its services. The synergy between Nova’s Optical CD technology and ReVera’s unique X-Ray Photoelectron Spectroscopy (XPS) technology will deliver leading edge solutions for superior process control at the most advanced technology nodes.

  • Kornit Digital Ltd. develops, designs and markets innovative digital printing solutions for the global printed textile industry. Kornit's solution includes its proprietary digital printing systems, ink and other consumables, associated software and value added services. Kornit's vision is to revolutionize the textile industry by facilitating the transition from analog processes that have not evolved for decades to digital methods of production that address contemporary supply, demand and environmental dynamics. Kornit is a global company headquartered in Rosh-Ha`Ayin, Israel, with U.S. offices in Mequon, Wisconsin and additional sales, support and marketing offices in Germany and Hong Kong.

    Kornit Digital Ltd. (NASDAQ: KRNT) raised $81.7 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,065,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Kornit Digital for general corporate purposes including working capital, to increase our visibility in the marketplace, to create a public market for our ordinary shares and to facilitate our future access to the public equity markets.

  • SolarEdge provides an intelligent inverter solution that has changed the way power is harvested and managed in solar photovoltaic systems. The SolarEdge DC optimized inverter system maximizes power generation at the individual PV module-level while lowering the cost of energy produced by the solar PV system. The SolarEdge system consists of power optimizers, inverters and a cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations.

    SolarEdge Technologies (NASDAQ: SEDG) raised $144.9 million in its initial public offering at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,050,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SolarEdge Technologies for general corporate purposes, including working capital and expansion of their business into additional markets.

  • BEEcube is a technology innovator and leading supplier of advanced all programmable real-time signal processing platforms used in communications, defense, education and research for real-time prototyping, academic research, military communications, surveillance/signal intelligence and advanced wireless research/5G and infrastructure deployment. BEEcube will operate as a wholly-owned NI subsidiary going forward.

    BEEcube, a technology innovator and leading supplier of high-performance FPGA prototyping and deployment products for advanced wireless research, completed its previously announced sale to National Instruments (NASDAQ: NATI)., the provider of platform-based systems that enable engineers and scientists to solve the world’s greatest engineering challenges. BEEcube will operate as a wholly-owned NI subsidiary. The terms of the transaction have not been publicly disclosed. Needham acted as financial advisor to BEEcube on this transaction.

  • Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

    Esperion Therapeutics, Inc. (NASDAQ: ESPR) raised $201.3 million in its follow-on offering at $100.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 262,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering as well as its other existing capital resources, will be used by Esperion Therapeutics, Inc. to complete the clinical development of ETC-1002, including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.

  • HubSpot is the world’s leading inbound marketing and sales platform. Since 2006, HubSpot has been on a mission to make the world more inbound. Today, over 12,000 customers in more than 75 countries use HubSpot’s software, services, and support to transform the way they attract, engage, and delight customers. HubSpot’s inbound marketing software, ranked #1 in customer satisfaction by VentureBeat and G2Crowd, includes social media publishing and monitoring, blogging, SEO, website content management, email marketing, marketing automation, and reporting and analytics, all in one integrated platform. Sidekick, HubSpot’s award-winning sales application, enables sales and service teams to have more effective conversations with leads, prospects, and customers. HubSpot is headquartered in Cambridge, MA with an office in Dublin, Ireland, and has been recognized by Inc., Forbes, and Deloitte as one of the world’s fastest-growing companies.

    HubSpot, Inc. (NYSE: HUBS) raised $175.1 million in its follow-on offering at $37.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 617,172 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by HubSpot, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

    Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $51.75 million in its follow-on offering at $8.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 818,181 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences primarily for preclinical and clinical development of our lead product candidates, discovery, research and development of other product candidates and other corporate purposes.

  • Mandalay Digital Group, Inc., through its wholly owned subsidiary, Digital Turbine, provides mobile solutions for wireless carriers globally to enable them to better monetize mobile content. The Company's products include mobile application management through DT Ignite, user experience and discovery through DT IQ, application stores and content through DT Marketplace, and content management and mobile payments through DT Pay. With global headquarters in Los Angeles, and offices in the U.S., Asia Pacific and EMEA, Mandalay Digital's solutions are used by more than 31 million consumers each month across more than 20 global operators.

    Mandalay Digital Group (Nasdaq:MNDL) announced that it has completed the acquisition of Appia, the leading independent mobile user acquisition network, in a stock-for-stock transaction. Appia shareholders received approximately 19 million shares of newly issued Digital Turbine stock, or approximately 33% of the combined company. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Mandalay Digital Group as part of its services.

  • Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially improve the competitive standing of these businesses and enhance their value for employees, customers and shareholders. Among Vector's notable investments are Aladdin Knowledge Systems, Allegro Development, Cambium Networks, Certara, CollabNet, Corel, IPVALUE Management, LANDesk Software, Niku, Gerber Scientific, RAE Systems, Register.com, Saba, SafeNet, Technicolor, Teletrac, Tidel, Triton Digital, WatchGuard Technologies and WinZip.

    Vector Capital announced that it has completed the acquisition of ChyronHego Corporation, a leading provider in broadcast graphics creation, play-out and real-time data visualization offering a wide variety of products and services for live television, news and sports production, for a net purchase price of $120 million in cash. Needham & Company acted as a financial advisor to Vector Capital on this transaction.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo™ for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite® for bacterial conjunctivitis and BromSite™ for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors. Nicox is headquartered in France.

    Nicox S.A. (Euronext Paris: COX) completed the pricing financing of 15 million shares at €1.80, for gross proceeds of approximately €27 million or $28.53 million through a private placement made to specific categories of investors. Needham acted as co-placement agent for this transaction. The net proceeds from the sale of the shares will be used by Nicox to provide additional resources to the Company to finance its strategy, in particular: *Working capital and general corporate purposes. *Clinical development and regulatory filings related to pipeline candidates. *Strengthening the Company’s commercial organization in Europe and the United States. *Listing of new shares.

  • MaxPoint provides a leading business intelligence and digital marketing solution that enables national brands to drive local, in-store sales. The company’s proprietary Digital Zip® technology and the MaxPoint Intelligence Platform predict the most likely local buyers of a specific product at a particular retail location and then execute cross-channel digital marketing campaigns to reach these buyers. MaxPoint has worked with each of the top 20 leading national advertisers and each of the top 10 advertising agencies in the United States as ranked by Advertising Age.

    MaxPoint Interactive, Inc. (NYSE: MXPT) raised $74.8 million in its initial public offering at $11.50 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by MaxPoint Interactive for general corporate purposes, including working capital, sales and marketing activities, engineering initiatives including enhancement of our solution, investment in technology and development and capital expenditures.

  • Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.

    Summit Therapeutics (NASDAQ: SMMT) raised $39.3 million in its initial public offering at $9.90 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 517,500 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Summit Therapeutics for general corporate purposes including working capital, product development and operating expenses.

  • Q2 is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

    Q2 Holdings, Inc. (NYSE: QTWO) raised $116.34 million in its upsized follow-on offering at $19.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 768,352 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the Q2 Holdings for working capital and other general corporate purposes, including to finance their expected growth, develop new technologies, fund capital expenditures, or expand the company's existing business through investments in or acquisitions of other businesses or technologies.

  • Quintic is the supplier of QBlue, a world class Bluetooth Low Energy product line. Leveraging their expertise in ultra-low power and high performance RF IC design, Quintic is delivering leading wireless connectivity and control solutions for consumer electronics, wearable devices and their peripherals.

    Quintic Microelectronics completed its previously announced sale of its assets and IP related to its Wearable and Bluetooth Low Energy (BTLE) IC business to NXP semiconductors N.V. (NASDAQ: NXPI), creator of solutions that enable secure connections for a smarter world. The transaction contributes to NXP’s drive to create security and connectivity solutions for Internet-of-Things applications in Health & Fitness Wearables, Mobile Transactions, Proximity Marketing, Smart Home and Automotive. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Quintic on this transaction.

  • 3D Systems is pioneering 3D design and fabrication for everyone. 3DS provides the most advanced and comprehensive solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful ecosystem empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS' leading 3D healthcare solutions include end-to-end simulation, training and planning and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. Its democratized 3D digital design, fabrication and inspection products provide seamless interoperability between subtractive and additive manufacturing and incorporate the latest immersive computing technologies. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

    3D Systems (NYSE:DDD), is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike announced that it has completed the acquisition of Cimatron Ltd. (Nasdaq:CIMT), a leading provider of integrated CAD/CAM software solutions for the toolmaking and manufacturing industries for approximately $97 million, inclusive of Cimatron's net cash. Needham & Company served as exclusive financial advisor to 3D Systems on this transaction.

  • Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma.

    Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) raised $202.4 million in its follow-on offering at $176.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 150,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Intercept Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • Oerlikon is a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation. Based on these core competencies, Oerlikon develops production systems, components, and services for high-technology products. The company's commercial activities center on turn-key solutions for the manufacturing of protective coatings for precision tools and components (Surface Solutions Segment), systems for producing vacuums and conveying process gases (Vacuum Segment), equipment for textile production (Manmade Fibers Segment) and propulsion technology (Drive Systems Segment).

    OC Oerlikon Corporation AG (SIX: OERL), a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation, announced the successful closing of the sale of its Advanced Technologies Segment to Evatec AG, a customer-focused business which produces its thin-film deposition products to the highest standards. Both capital equipment businesses are well positioned in their respective markets by delivering complete thin film production solutions and services to their customers around the globe. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Oerlikon on this transaction.

  • BTU International, Inc. is global supplier and technology leader of advanced thermal processing equipment and processes to the electronics and alternative energy manufacturing markets. BTU equipment is used in the production of printed circuit board assemblies and semiconductor packaging as well as in solar cell and nuclear fuel manufacturing.

    BTU International, Inc. (NASDAQ: BTUI), a global supplier of advanced thermal processing equipment to the electronics and alternative energy manufacturing markets, completed its previously announced sale to Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers. Under the terms of the merger agreement, BTU shareholders received 0.3291 shares of Amtech common stock per share of BTU common stock. The transaction valued BTU at approximately $26.2 million based on Amtech’s close price on Friday, January 30, 2015. Needham & Company acted as exclusive financial advisor to BTU International on the transaction.

  • NeuLion, Inc. offers the true end-to-end solution for delivering live and on-demand content to Internet-enabled devices. NeuLion enables content owners and distributors, cable operators and telecommunications companies to capitalize on the massive consumer demand for viewing video content on PCs, smartphones, iPads and other similar devices. NeuLion's customers include major entertainment, sports, global content and news companies. NeuLion is based in Plainview, NY.

    NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, announced that it has completed the acquisition of DivX Corporation, a leading provider of next-generation digital video solutions. The total transaction value is approximately $62.5 million. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of NeuLion, Inc. as part of its services.

  • Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

    Omeros Corporation (NASDAQ: OMER) raised $84 million in its follow-on offering at $20.03 per share of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 449,325 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Omeros Corporation for general corporate purposes, including expenses related to the commercialization of Omidria™, research and development expenses, such as funding clinical trials, preclinical studies, manufacturing development and costs associated with otherwise advancing the company's drug candidates toward New Drug Application submission. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

  • TRACON Pharmaceuticals, Inc. develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

    TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) raised $36 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by TRACON Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) raised $517.5 million in its follow-on offering at $95 per share. Needham acted as the co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 710,526 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Alnylam Pharmaceuticals for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020.

  • Sanbolic is an innovator and leader in workload-oriented storage virtualization technologies. Sanbolic technology enables customers to software-define storage to optimize the delivery of application-specific workloads, from any media type – SSD, Flash and hard drives in NAS, SAN, server-side and cloud deployments – improving storage load balancing, application availability and delivering the highest-performance end-user experience.

    Sanbolic, an innovator and leader in workload-oriented storage virtualization technologies, completed its previously announced sale to Citrix Systems, Inc. (NASDAQ: CTXS), a leader in mobile workspaces, providing virtualization, mobility management, networking and cloud services to enable new ways to work better. The terms of the acquisition were not disclosed. Needham & Company served as exclusive financial advisor to Sanbolic on this transaction.

  • Aeglea (NASDAQ: AGLE) is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

    Aeglea BioTherapeutics, Inc. raised $54.82 million in its upsized initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 481,940 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Aeglea BioTherapeutics, Inc. for general corporate purposes including working capital, product development and operating expenses.

  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies.

    Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency (RF) solutions for the growing CATV infrastructure, small-cell, WiFi, and cellular markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional reliability, performance and integration to deliver a unique competitive advantage to OEMs and ODMs for infrastructure and mobile applications. The Company’s award-winning solutions include line amplifiers, upstream amplifiers, power amplifiers, front-end ICs, front-end modules and other RF components.

    ANADIGICS, Inc. (NASDAQ: ANAD), a world leader in radio frequency (RF) solutions, completed its previously announced sale to II‐VI Incorporated (NASDAQ: IIVI), a leader in engineered materials and optoelectronic components for approximately $78.2 million in cash. Needham & Company acted as the exclusive financial advisor to ANADIGICS, Inc.

  • IntegriChain is the leading channel management cloud used by life sciences suppliers, including nine of the top 10 pharmaceutical manufacturers, to drive channel collaboration and to improve the efficiency of how products reach customers. Pharmaceutical, biopharm/specialty pharma, generics, and consumer health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. As a suite of informed applications and analytics built on top of aggregated channel inventory and point-of-sale (POS) data, IntegriChain provides customer operations, national accounts, and finance teams with a collaborative, agile, and mobile alternative to ERP and homegrown systems. By embedding big-data customer insights into daily business processes, IntegriChain helps control the high cost of product distribution while improving product availability, ensuring a higher level of revenue predictability and maximizing distribution investment. More than $200 billion in annual U.S. commerce and 2 billion transactions flow through the IntegriChain Cloud annually. IntegriChain is backed by Accel-KKR, a leading technology private equity firm.

    IntegriChain, the leading channel management cloud used by life sciences suppliers has received a strategic equity investment from Accel-KKR, a technology-focused investment firm with $4.0 billion in capital commitments to its current funds. Under the terms of the investment, Accel-KKR will acquire 100% of the equity not held by members of IntegriChain's management team. Needham & Company acted as the exclusive financial advisor to IntegriChain.

  • ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

    ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.

  • PMC (NASDAQ: PMCS) is the semiconductor and software solutions innovator transforming networks that connect, move and store big data. Building on a track record of technology leadership, PMC is driving innovation across storage, optical and mobile networks. PMC's highly integrated solutions increase performance and enable next-generation services to accelerate the network transformation.

    PMC-Sierra, Inc., a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC) ("Microsemi"), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, PMC-Sierra's shareholders have received $9.22 in cash and 0.0771 of a share of Microsemi common stock for each share of PMC common stock through an exchange offer. Needham & Company acted as a financial advisor to PMC-Sierra, Inc.

  • Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $55.0 million in its follow-on offering at $20.00 per share. Needham acted as co-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia has completed Phase 2 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients. Enrollment in the PRO2TECT™ Phase 3 program in non-dialysis patients commenced in late 2015 and the INNO2VATE™ Phase 3 program in dialysis-dependent CKD patients is expected to commence in 2016.

    Akebia Therapeutics, Inc. raised $65.3 million in its follow-on offering at $9.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. offering to fund continued clinical development of vadadustat in patients with anemia secondary to chronic kidney disease (CKD), including to prepare, initiate and conduct its PRO2TECT™ Phase 3 program and to prepare and initiate its planned INNO2VATE™ Phase 3 program, to advance AKB-6899 through Phase 1 development in oncology, and the remainder for working capital and other general corporate purposes.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

    ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C.

    Cempra, Inc. raised $100.0 million in its follow-on offering at $24.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. to fund the commercial launch of solithromycin in community acquired bacterial pneumonia (CABP) in the U.S., subject to the drug receiving FDA approval for such an indication, research and development activities, including the continued clinical and regulatory development of solithromycin in CABP and gonorrhea and Taksta in acute bacterial skin and skin structure infections (ABSSSI) and also for the chronic oral treatment of refractory infections in bones and joints, as well as for working capital and general corporate and administrative expenses.

  • Yirendai (NYSE: YRD) is a leading online consumer finance marketplace in China connecting investors and individual borrowers. The Company provides an effective solution to address largely underserved investor and individual borrower demand in China through an online platform that automates key aspects of its operations to efficiently match borrowers with investors and execute loan transactions. Yirendai deploys a proprietary risk management system, which enables the Company to effectively assess the creditworthiness of borrowers, appropriately price the risks associated with borrowers, and offer quality loan investment opportunities to investors. Yirendai's online marketplace provides borrowers with quick and convenient access to consumer credit at competitive prices and investors with easy and quick access to an alternative asset class with attractive returns.

    Yirendai Ltd. raised $75 million in its initial public offering at $10.00 per share. Needham acted as a passive bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Yirendai Ltd. for general corporate purposes, which may include investment in product development, sales and marketing activities, technology infrastructure, capital expenditures, improvement of corporate facilities and other general and administrative matters. The company may also use a portion of these proceeds for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business.

  • Pertino is a new way to WAN for the mobile and cloud era—secure, software-defined and delivered as a service. Mobile and cloud technologies are transforming IT, resulting in a hybrid IT model where distributed workforces and workloads are reliant on the Internet. Our Cloud Network Engine platform enables enterprises to build and manage private cloud networks that overlay the public Internet, securely connecting people, devices and resources anywhere. With AppScape, our network services app store, Pertino cloud networks can be extended with enterprise-level visibility, security and control services. This modern approach to networking combines the power and pervasiveness of the cloud with SDN and virtualization technologies to eliminate cost and complexity. Finally, a WAN that is cloud-agile and works the way organizations work today, without hardware, hassles, or high costs. Founded in 2011, Pertino is venture funded by premier firms and headquartered in Los Gatos, California.

    Pertino, a privately-held Silicon Valley company that has pioneered the use of software-defined networking to deliver cloud-based networks as-a-service for enterprise and SMB customers worldwide, completed its previously announced sale to Cradlepoint, the global leader in software-defined 4G LTE network solutions for enterprises. The terms of the transaction were not disclosed. Needham & Company acted as the exclusive financial advisor to Pertino.

  • The Chinese consortium of investors was led by SummitView Capital and includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management. Summitview Capital is a private equity firm specializing in buyouts. It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry. Summitview Capital is based in Shanghai China, with an additional office in Changzhou, China.

    A Chinese consortium of investors led by SummitView Capital and that includes eTown MemTek, Hua Capital, and Huaqing Jiye Investment Management announced that it has completed the acquisition of Integrated Silicon Solution, Inc. (NASDAQ: ISSI), a global fabless semiconductor company, for a net purchase price of $782.6 million in cash. Needham & Company acted as a financial advisor to the Chinese consortium.

  • Inphi Corporation (NYSE: IPHI) is a leading provider of high-speed, mixed-signal semiconductor solutions for the communications, computing and data center markets. Inphi’s end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi’s solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi’s solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms.

    Inphi Corporation issued $230.0 million principal amount of Convertible Senior Notes due 2020. The size of the offering was increased to $200.0 from the previously announced $150.0 million aggregate principal amount. Prior to June 1, 2020, the notes will be convertible only under certain circumstances and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The initial conversion rate for the notes will be 24.8988 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $40.16 per share, and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 35.0% over the last reported sale price of $29.75 per share of Inphi's common stock on The New York Stock Exchange on December 2, 2015. Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction.

  • Instructure, Inc. (NYSE: INST) is a leading software-as-a-service (SaaS) technology company that makes software that makes people smarter. With a vision to help maximize the potential of people through technology, Instructure created Canvas and Bridge to enable organizations everywhere to easily develop, deliver and manage engaging face-to-face and online learning experiences. To date, Instructure has connected millions of teachers and learners at more than 1,800 educational institutions and corporations throughout the world.

    Instructure, Inc. raised $81.0 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 660,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Instructure, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development activities, general and administrative matters and capital expenditures. They may also use a portion of the net proceeds from this offering for acquisitions of, or investments in, technologies, solutions or businesses that complement the business.

  • Xoom Corporation (NASDAQ: XOOM) is a leading digital money transfer provider that enables consumers to send money, pay bills and send mobile reloads to family and friends around the world in a secure, fast and cost-effective way, using their mobile phone, tablet or computer. During the 12 months ended March 31, 2015, Xoom’s more than 1.3 million active customers sent approximately $7.0 billion with Xoom.

    Xoom Corporation, a digital money transfer provider, completed its previously announced sale to PayPal, Inc. (NASDAQ: PYPL), a provider of a worldwide online payments system. In accordance with the terms of the acquisition agreement announced on July 1, 2015, PayPal acquired all of the outstanding shares of Xoom for $25 per share in cash. Xoom will operate as a separate service within PayPal. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Xoom Corporation as part of its services.

  • Xtera Communications, Inc. (NASDAQ: XCOM) is a leading provider of high-capacity, cost-effective optical transport solutions, supporting the high growth in global demand for bandwidth. Xtera sells solutions to telecommunications service providers, content service providers, enterprises and government entities worldwide. Xtera’s proprietary Wise RamanTM optical amplification technology leads to capacity and reach performance advantages over competitive products. Xtera’s solutions enable cost-effective capacity to meet customers’ bandwidth requirements of today and to support their increasing bandwidth demand fueled by the development of data centers and related cloud-based services.

    XTERA Communications Inc. raised $25.0 million in its offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by XTERA Communications Inc. for working capital and other general corporate purposes, including to finance our expected growth, develop new products or fund capital expenditures. The Company may also use a portion of the net proceeds to repay borrowings under its credit facility or term loan, or to expand its existing business through acquisitions of other businesses, products or technologies.

  • LendingTree, Inc. (NASDAQ: TREE) operates a leading online loan marketplace and provides consumers with an array of online tools and information to help them find the best loans for their needs. The Company's online marketplace connects consumers with multiple lenders that compete for their business, empowering consumers as they comparison-shop across a full suite of loans and credit-based offerings. The Company provides access to lenders offering home loans, home equity loans/lines of credit, reverse mortgages, personal loans, auto loans, small business loans, credit cards, student loans and more.

    LendingTree, Inc. raised $112.41 million in its follow-on offering at $115.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 127,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by LendingTree, Inc. for general corporate purposes, including but not limited to, working capital and potential acquisitions.

  • iboss Cybersecurity defends today’s large, distributed organizations against targeted cyber threats which lead to data loss, with the iboss next-gen Secure Web Gateway Platform, leveraging innovative cloud architecture and patented advanced threat defense technologies. iboss advanced solutions deliver unparalleled visibility across all inbound/outbound data channels, and include security weapons that reveal blind spots, detect breaches and minimize the consequences of data exfiltration. With leading threat protection and unsurpassed usability, iboss is trusted by thousands of organizations and millions of users.

    iBoss, Inc. raised $35.0 million in Series A funds from Goldman Sachs’ Private Capital Investing group. The new financing will allow iboss to aggressively develop groundbreaking technology, including the rollout of its next-generation cloud platform, while continuing to expand globally. Needham acted as the sole placement agent for this transaction.

  • Adesto Technologies Corporation (NASDAQ: IOTS) offers the world’s lowest power memory solutions unleashing innovation for a new class of connected applications and previously unimagined devices. The company has designed and built a portfolio of innovative products, including Fusion Serial Flash, DataFlash® and Mavriq™ serial memory. Adesto holds more than 100 patents with dozens more in process and is working with visionary companies across various industries to deploy its technology to the market.

    Adesto Technologies Corporation raised $25.0 million in its initial public offering at $5.00 per share. Needham acted as the lead bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Adesto Technologies Corporation use the net proceeds from this offering for working capital and other general corporate purposes, to acquire or invest in complementary businesses, products, services, technologies or other assets, and for potential pay down of a $15.0 million term loan facility.

  • Intronis provides data protection solutions for small businesses, delivered exclusively through the IT channel. The Intronis ECHOplatform securely protects physical and virtual data with native support for physical imaging,VMware, Hyper-V, Exchange, and SQL, all through a re-brandable central management console that integrates with major RMM and PSA tools. With Intronis' fixed-fee storage pricing per SMB account, IT service providers are able to streamline their pricing strategy and simplify their account management.

    Intronis, Inc. (NASDAQ: SWTX), a leader in providing data protection solutions to managed service providers (MSPs), a fast-growing channel delivering IT services to small and medium-sized businesses, completed its previously announced sale to Barracuda Networks, Inc. (NYSE: CUDA), a provider of cloud-connected security and storage solutions that simplify IT, in an all cash transaction. Needham & Company acted as a financial advisor to Intronis, Inc..

  • Netsertive’s digital marketing intelligence platform empowers brands and local businesses to work together to win local customers. The company’s two complementary solutions, MarketWise™ for Brands and StreetWise™ for Local Businesses, enable cooperative marketing and resource sharing between brands and their local business partners. Both are powered by Netsertive's proprietary learning engine, which combines the company's deep industry experience with the collective intelligence of its extensive network of automotive, IT technology, major appliance, furniture, consumer electronics and healthcare clients to deliver unprecedented campaign speed, performance and value. An award-winning marketing technology company and Google Premier SMB Partner, Netsertive drives local marketing success from campaign enablement through scaled, local execution. Additionally, Netsertive helps brands with their co-op marketing to ensure localized brand compliance, seamless campaign execution and reimbursement tracking for local partners. Founded in 2009 and based in Research Triangle Park, North Carolina, the company has a history of rapid growth, a world-class team and the strength of venture capital funding from top firms RRE Ventures, Harbert Venture Partners, River Cities Capital Funds and Greycroft Partners. Netsertive was named 2014 Software Company of the Year by North Carolina Technology Association and was named among Inc. Magazine’s 500 fastest-growing private companies three years in a row.

    Netsertive raised $15 million in Series C growth financing. River Cities Capital Funds led the round and will be joined by existing investors. The new round will fuel Netsertive’s acceleration in the digital marketing technology arena, as it continues to add major brands for its MarketWise™ solution and local businesses for its StreetWise™ solution. Needham & Company served as exclusive placement agent on this transaction.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases.

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) raised $126.8 million in its follow-on offering at $39.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. for product and commercial development, manufacturing, any business development activities and for general corporate purposes.

  • Dot Hill Systems Corp. (NASDAQ: HILL) solves today's storage workload challenges created by the Internet of Things and third platform technologies leveraging its proprietary AssuredSAN family of hybrid storage solutions with RealStor, the next generation real-time storage operating system. In today's interconnected world, Dot Hill storage solutions support people accessing information, and machines collecting sensor data, all in real time. Dot Hill's solutions combine innovative intelligent software with the industry's most flexible and extensive hardware platform and simplified management to deliver best-in-class solutions. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in the United States, Europe, and Asia.

    Dot Hill Systems Corp. (NASDAQ: HILL), a leading innovator of energy-saving films and glass products for automotive and architectural markets, completed its previously announced sale to Seagate Technology plc (NASDAQ: STX), a world leader in storage solutionsin an all cash transaction. Needham & Company acted as a financial advisor to Dot Hill Systems and provided a fairness opinion to its Board of Directors as part of its services.

  • Medgenics, Inc. (NASDAQ: MDGN) is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases.

    Medgenics, Inc. raised $46.01 million in its follow-on offering at $6.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 923,250 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Medgenics, Inc. for for product development activities, including (a) the development of technologies acquired in the previously announced acquisition of neuroFix, LLC, (b) patent maintenance fees and intellectual property support, (c) licensing and research collaborations and (d) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses and making certain payments in connection with the acquisition of neuroFix, LLC, including an expected $2.8 million payment to satisfy a specific corporate milestone payment to the former stockholders of neuroFix, LLC.

  • Ikanos Communications, Inc. (NASDAQ: IKAN) is a leading provider of advanced broadband semiconductor and software products for the connected home. The company’s broadband DSL, communications processors and other offerings power access infrastructure and customer premises equipment for many of the world’s leading network equipment manufacturers and telecommunications service providers.

    Ikanos Communications, Inc. (NASDAQ: IKAN), a high performance broadband networking semiconductor and software provider enabling both central office and home gateway solutions, completed its previously announced sale to Qualcomm Incorporated (NASDAQ: QCOM), a world leader in 3G, 4G and next-generation wireless technologies. Pursuant to the agreement, Qualcomm Atheros, through a wholly-owned subsidiary, acquired all of the issued and outstanding shares of common stock of Ikanos for $2.75 per share in cash, and assumed all outstanding indebtedness at the closing of the transaction. Needham & Company acted as a financial advisor to Ikanos and provided a fairness opinion to the Board of Directors of Ikanos as part of its services. .

  • 2U, Inc. (NASDAQ: TWOU) partners with leading colleges and universities to deliver the world's best online degree programs so students everywhere can reach their full potential. Our Platform, a fusion of cloud-based software-as-a-service technology and technology-enabled services, provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate students globally.

    2U, Inc. (NASDAQ: TWOU) raised $136.9 million in its follow-on offering at $34.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 525,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by 2U, Inc. for general corporate purposes, including expenditures for program marketing, sales, technology, and content development, in connection with new program launches and growing existing programs.

  • Q2 Holdings, Inc. (NASDAQ: QTWO) is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

    Q2 Holdings, Inc. (NASDAQ: QTWO) raised $111.41 million in its follow-on offering at $25.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 569,850 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Q2 Holdings for general corporate purposes and working capital, including to finance their expected growth, develop new technologies, fund capital expenditures, or expand their existing business through investments in or acquisitions of other businesses or technologies.

  • Paylocity Holding Corporation (NASDAQ: PCTY) is a provider of cloud-based payroll and human capital management, or HCM, software solutions for medium-sized organizations. Paylocity's comprehensive and easy-to-use solutions enable its clients to manage their workforces more effectively. Paylocity's solutions help drive strategic human capital decision-making and improve employee engagement by enhancing the human resource, payroll and finance capabilities of its clients.

    Paylocity Holding Corporation (NASDAQ: PCTY) raised $128.0 million in its follow-on offering at $29.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 561,000 shares of common stock at the follow-on offering price to cover over-allotments. The shares of common stock offered by this prospectus are being registered for the account of the selling stockholders named in the prospectus. As a result, all proceeds from the sales of the common stock will go to the selling stockholders and Paylocity will not receive any proceeds from the resale of the common stock by the selling stockholders.

  • Nabriva Therapeutics AG (NASDAQ: NBRV) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

    Nabriva Therapeutics AG (NASDAQ: NBRV) raised $106.1 million in its initial public offering at $10.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,350,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nabriva to complete the clinical development of lefamulin for CABP, to submit applications for marketing approval for lefamulin for CABP in both the United States and Europe, to pursue the clinical development of lefamulin for additional indications, for earlier stage research and development activities and for working capital and other general corporate purposes.

  • Synacor (NASDAQ:SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises. We deliver modern, multiscreen experiences and advertising to their consumers that require scale, actionable data and sophisticated implementation.

    Synacor Inc. (NASDAQ:SYNC), the trusted multiscreen technology and monetization partner for video, internet and communications providers, device manufacturers, and enterprises, announced that it has completed the acquisition of Zimbra, Inc., a global leader in open source email, calendaring, and collaboration software, for a net purchase price of $24.5 million, with Synacor paying $17.3M in cash, issuing 3M shares, 0.6M warrants priced at $3.00 per share, and paying up to $2M in earn-outs over the next 18 months. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Synacor as part of its services.

  • Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

    Trevena, Inc. (NASDAQ: TRVN) raised $72.9 million in its follow-on offering at $9.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 975,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with its existing cash and investments will be used by Trevena, Inc. to complete Phase 3 development, submit a new drug application, and begin launch preparations for TRV130; to complete its Phase 2b BLAST-AHF study for TRV027; to complete initial Phase 1 studies for TRV250; to continue drug discovery in new therapy areas; and for working capital and general corporate purposes. Needham has now been part of three transactions for Trevena, including its initial public offering in February 2014.

  • Seattle Genetics, Inc. (NASDAQ: SGEN) is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.

    Seattle Genetics, Inc. (NASDAQ: SGEN) raised $552.0 million in its follow-on offering at $41.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,756,097 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Seattle Genetics to fund the ongoing commercialization of ADCETRIS in the United States and Canada, to fund research and development efforts designed to further expand the ADCETRIS label and to advance its pipeline of product candidates, as well as for general corporate purposes, including working capital. The Company may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property. This is the fourth transaction for Seattle Genetics where Needham has been part of the deal team since 2008.

  • Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox’s lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. AQX-1125 has demonstrated preliminary safety and favorable drug properties in multiple preclinical studies and clinical trials. The Firm is currently developing AQX-1125 as an oral, once daily treatment in bladder pain syndrome/interstitial cystitis (BPS/IC). In addition, it is exploring AQX-1125 for atopic dermatitis (AD) in its ongoing Kinship Phase 2 trial. For AQX-1125, the Company retains full worldwide rights and holds patents with terms through at least 2024. Aquinox uses a proprietary screening approach to discover new drug candidates that selectively target SHIP1 to modulate activated immune cells while minimizing their toxicity to normal cells. The Company’s intellectual property covers SHIP1 as a target, the C2 binding domain for screening and the composition of matter for its compounds. Aquinox has an extensive chemical library and several candidate lead compounds that target SHIP1. These compounds have both similar and distinct properties from AQX-1125. The Company believes AQX-1125 is the only SHIP1 activator currently in clinical trials and that no other SHIP1 activator has to date reported data from clinical trials or received marketing approval as a treatment for disease in humans.

    Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) raised $98.04 million in its follow-on offering at $15.50 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals for the clinical development of AGX-1125 in BPS/IC, for research, development and manufacturing of product candidates, and for other general corporate purposes.

  • Autonet Mobile Inc. is a world leading application and service provider for cars. Founded in 2005, Autonet Mobile was the first to deliver in-vehicle Wi-Fi with OE compatibility along with new technologies that support applications that allow owners to access their car from their phones to new forms of security.

    Autonet Mobile, a Santa Rosa company that develops devices and software to connect cars to the Internet, has sold its technology to Michigan auto parts giant Lear Corporation (NYSE: LEA). As part of the deal, Lear hired an undisclosed number of Autonet Mobile’s engineering and research and development workers. As part of the agreement announced this week, Lear acquired technology that uses cellular networks to connect on-board vehicle systems with cloud-based applications. Financial terms were not disclosed. Autonet Mobile will continue to use the technology it sold to Lear to support programs with existing customers and to develop new products for the automotive aftermarket, under a license agreement. Needham & Company acted as a financial advisor to Autonet Mobile, Inc..

  • Corium International, Inc. (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience in advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders.

    Corium International, Inc. (NASDAQ: CORI) raised $52.0 million in its follow-on offering at $13.00 per share. Needham acted as lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Corium International for general corporate purposes, which may include funding research and development, increasing working capital, acquisitions or investments in businesses, products or technologies that are complementary to Corium’s own businesses and capital expenditures.

  • Dermira, Inc. (NASDAQ: DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $111.3 million in its follow-on offering at $21.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 675,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all product candidates, working capital, capital expenditures and other general corporate purposes.

  • Selectica, Inc. (NASDAQ: SLTC) provides a platform for enterprises worldwide to create, manage, and optimize business relationships with contracts at the core. Selectica helps global companies actively manage their contracts throughout the sales, procurement, and legal life cycles. Selectica's contract management solutions drive business value by assisting organizations in managing contracts profitably, effectively accelerating revenue opportunities, and minimizing risk through compliance. Through IASTA, a Selectica company, we provide leading supply management and spend management solutions, dedicated to empowering sourcing and purchasing professionals. Our blend of acclaimed software and services focus on improving spend analysis, procurement intelligence, sourcing, and supplier life cycle management. Our solutions play a critical role in optimizing business relationships by enhancing supply base insights, improving supplier collaboration and reducing the supply chain risks vital to today's globally-minded enterprise. Selectica also provides a powerful configuration engine, enabling Fortune 500 companies to accelerate revenue by facilitating the optimization of the right combination of products, services, and price.

    Selectica, Inc. (NASDAQ: SLTC) announced that it has completed the acquisition of b-pack, a global leader in purchase-to-pay (P2P) software and services, for approximately $12.33 million in cash and stock. Needham & Company acted as a financial advisor to Selectica, Inc.

  • Genocea Biosciences, Inc. (NASDAQ: GNCA) is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

    Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $50.1 million in its follow-on offering at $13.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences to fund the clinical development of GEN-003 and GEN-004, continue investment in new research programs, and the balance for other general corporate purposes.

  • Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

    Cara Therapeutics, Inc. (NASDAQ: CARA) raised $80.5 million in its follow-on offering at $18.60 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 564,516 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cara Therapeutics to conduct planned clinical trials of I.V. CR845 and Oral CR845, to fund the research and development of preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes.

  • Intel Corporation (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world’s computing devices. Headquartered in Santa Clara, Calif., Intel today has more than 100,000 employees in 63 countries and serves customers in more than 120 countries. Intel today designs and manufactures a variety of essential technologies, including microprocessors and chipsets and the additional hardware, software, and related services that together serve as the foundation for many of the world’s computing devices. Over the last decade, Intel has evolved from a company that largely serves the PC industry, to a company that increasingly provides the vital intelligence inside all things computing. In fact, one-third of Intel's revenue is associated with products beyond the PC. Hardware and software products by Intel and subsidiaries such as McAfee, power the majority of the world’s data centers, connect hundreds of millions of cellular handsets and help secure and protect computers, mobile devices and corporate and government IT systems. Intel technologies are also inside intelligent systems, such as in automobiles, automated factories and medical devices.

    Intel Corporation (NASDAQ: INTC) issued $7.0 billion principal amount of Convertible Senior Unsecured Notes to finance part of its $16.7 billion takeover of Altera Corp. Needham & Company acted as a co-manager for this transaction.

  • Xactly Corporation (NYSE:XTLY) is a leading provider of enterprise-class, cloud-based, incentive compensation solutions for employee and sales performance management. They address a critical business need: To incentivize employees and align their behaviors with company goals. Xactly's products allow organizations to make more strategic decisions, increase employee performance, improve margins, and mitigate risk. Our core values are key to our success, and each day we’re committed to upholding them by delivering the best we can to their customers.

    Xactly Corporation raised $67.4 million in its initial public offering at $8.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,055,625 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Xactly Corporation for for working capital and other general corporate purposes. The Company also may use a portion of the net proceeds to acquire or invest in complementary businesses, products, services, technologies or other assets.

  • Avid Technology, Inc. (NASDAQ: AVID) delivers the industry's most open, innovative and comprehensive media platform connecting content creation with collaboration, asset protection, distribution and consumption for the most listened to, most watched and most loved media in the world—from the most prestigious and award-winning feature films, music recordings, and television shows, to live concerts and news broadcasts. Industry leading solutions include Pro Tools®, Media Composer®, ISIS®, Interplay®, and Sibelius®.

    Avid Technology, Inc. (Nasdaq: AVID) announced that it has completed the acquisition of Orad Hi-Tec Systems Ltd., a Frankfurt stock exchange-listed public company with its headquarters in Kfar Saba, Israel, for €5.67 per share in an all-cash transaction. Orad is a leading provider of state-of-the-art 3D real-time graphics, video servers and related asset management solutions. The acquisition is consistent with Avid’s stated growth strategy and Avid believes it will continue to deliver on the company’s Avid Everywhere vision, by adding key content creation and media management solutions to the Avid MediaCentral Platform, the industry's most open, innovative and comprehensive media platform. Needham & Company acted as a financial advisor to Avid Technology, Inc.

  • NeoPhotonics Corporation (NASDAQ: NPTN) is a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks. The Company’s products enable cost-effective, high-speed data transmission and efficient allocation of bandwidth over communications networks. NeoPhotonics maintains headquarters in San Jose, California and ISO 9001:2000 certified engineering and manufacturing facilities in Silicon Valley (USA), Japan and China.

    NeoPhotonics Corporation raised $49.8 million in its follow-on offering at $7.25 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 895,655 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by NeoPhotonics Corporation for working capital, to continue to expand their existing business and general corporate purposes.

  • Auris Medical Holding AG (NASDAQ: EARS) is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.

    Auris Medical Holding AG raised $25.1 million in its follow-on offering at $4.75 per share. Needham acted as the joint-lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Auris Medical Holding AG to fund research and development expenses for AM-111, for early stage programs, working capital and other general corporate purposes.

  • Camtek Ltd. (NASDAQ: CAMT and TASE: CAMT), provides automated and technologically advanced solutions dedicated to enhancing production processes, increasing products yield and reliability, enabling and supporting customer's latest technologies in the Semiconductors, Printed Circuit Boards (PCB) and IC Substrates industries.

    Camtek, Ltd. raised $13.3 million in its follow-on offering at $2.85 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters exercised their option to purchase an additional 355,982 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Camtek, Ltd. for general corporate purposes.

  • Collegium Pharmaceuticals, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceuticals, Inc. raised $80.4 million in its initial public offering at $12.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 870,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Collegium Pharmaceuticals for the development of commercial infrastructure to launch Xtampza, to fund research and development efforts of additional product candidates, and to fund working capital and general corporate purposes.

  • N-Trig Ltd. is an Israel-technology company started in 1999 that owns more than 100 patents related to digital pens and related technology that helps enable customers to use natural handwriting for input on touch screens. Its technology has been used in dozens of consumer products from Dell, Lenovo, HP, Fujitsu, Sharp, Toshiba and other major OEMs. In 2014, an N-Trig pen became part of Microsoft’s Surface Pro 3 package.

    N-Trig Ltd, a leading innovator in digital pen technology, completed its previously announced sale of the Surface 3 Pen technology specifically and related assets, not the company as a whole to Microsoft Corporation (NASDAQ: MSFT), a multinational technology company that develops, manufactures, licenses, supports and sells computer software, consumer electronics and personal computers and services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to N-trig Ltd.

  • Vitesse (NASDAQ: VTSS) designs a diverse portfolio of high-performance semiconductors, application software, and integrated turnkey systems solutions for Carrier, Enterprise and Internet of Things (IoT) networks worldwide. Vitesse products enable the fastest-growing network infrastructure markets including Mobile Access/IP Edge, Cloud Access and Industrial-IoT Networking.

    Vitesse Semiconductor Corporation (NASDAQ: VTSS), designer of a diverse portfolio of high-performance semiconductors, application software, and integrated turnkey systems solutions for carrier, enterprise and Internet of Things (IoT) networks worldwide, completed its previously announced sale to Microsemi Corporation (Nasdaq: MSCC), a leading provider of semiconductor solutions differentiated by power, security, reliability and performance. Under the terms of the agreement, each outstanding share of Vitesse (other than shares directly owned by Vitesse and its subsidiaries, Microsemi or LLIU100 Acquisition Corp. and shares held by stockholders that are entitled to and properly demand appraisal of such shares under Delaware law) was converted into the right to receive $5.28 per share in cash, without interest and less any applicable withholding taxes, the same price that was paid in the tender offer. Needham acted as a financial advisor to Vitesse Semiconductor Corporation.

  • SCYNEXIS, Inc. (Nasdaq:SCYX) is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans.

    SCYNEXIS, Inc. (Nasdaq:SCYX) raised $41.4 million in its follow-on offering at $7.70 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 701,298 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by SCYNEXIS, Inc. for working capital, capital expenditures and other general corporate purposes, including preclinical and clinical costs associated with the IV formulation of SCY-078, clinical costs associated with the completion of an ongoing Phase 2 study of oral SCY-078 and the initiation of a study that includes both IV and oral SCY-078.

  • Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) raised $69.0 million in its follow-on offering at $8.25 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,090,909 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. to continue clinical development of AKB-6548 in patients with anemia secondary to chronic kidney disease, including the preparation for and initiation of Phase 3 trials, to advance its preclinical candidate, AKB-6899, through Phase 1 development in oncology, and to increase working capital, as well as for other general corporate purposes.

  • Pernix Therapeutics Holdings, Inc., is a specialty pharmaceutical company, that develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company's product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women's health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.

    Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) issued $130.0 million principal amount of the Company's 4.25% Convertible Senior Notes due 2021Convertible Senior Notes due 2016. The size of the offering was increased from the previously announced aggregate principal amount of $120 million. The notes will pay interest semi-annually at a rate of 4.25% per annum and will mature on April 1, 2021, unless redeemed, repurchased or converted in accordance with their terms prior to such date. The notes will have an initial conversion rate, subject to adjustment, of 87.2030 shares of the Company’s common stock per $1,000 principal amount of the notes, representing a conversion price of approximately $11.47 per share of the Company’s common stock, based on the last reported sale price of $8.34 per share of the Company’s common stock on April 16, 2015. Needham & Company acted as a co-manager for this transaction. Pernix Therapeutics expects to use $80.9 million of the gross proceeds from the offering to finance the cash consideration portion of the consideration necessary to consummate its previously announced acquisition of the Zohydro® ER franchise, approximately $8.3 million to pay fees and expenses related to such acquisition and the offering, up to $2.2 million to pay the consent fee related to the Company’s previously announced consent solicitation of its 12.00% senior secured notes due 2020 and the remainder for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.

  • Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial portfolio is comprised of a long-acting echinocandin antifungal product candidate, CD101 IV, and CD101 topical, for the treatment of serious fungal infections. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California.

    Cidara Therapeutics raised $76.8 million in its upsized initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Cidara Therapeutics for general corporate purposes including working capital, product development and operating expenses.

  • Cradlepoint is the global leader in cloud-managed 4G LTE networking solutions, providing industry-leading WWAN and Security solutions to distributed enterprises. Specializing in Business Continuity, M2M/IoT applications, Application Specific or Parallel Networking and Transportation networking, Cradlepoint's award-winning solutions are purpose built for PCI-compliant networks. Cradlepoint was the first to pioneer and fully enable high-speed LTE solutions to maximize the potential of the cloud for businesses worldwide. Cradlepoint is a privately held company in Boise, Idaho.

    Cradlepoint completed the pricing of a Series B round of $48 million in growth equity funding. Needham & Company served as sole placement agent on this transaction. The proceeds will be used to accelerate Cradlepoint’s international expansion and development of cloud-managed Wireless Wide Area Networks (WWAN) and security solutions.

  • Dyax Corp. is a biopharmaceutical company focused on: Hereditary Angioedema and Other Plasma-Kallikrein-Mediated (PKM)Disorders. It develops and commercializes treatments for hereditary angioedema and Dyax Corp. is working to identify additional disorders that are mediated by plasma kallikrein.

    Dyax Corp. (NASDAQ: DYAX) raised $229.8 million in its follow-on offering at $27.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,110,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dyax Corp. for to develop and, if approved, commercialize DX-2930 worldwide for the prophylactic treatment of hereditary angioedema, for research and development of product candidates to address additional plasma-kallikrein-mediated (PKM) disorders and other orphan diseases outside the PKM pathway, to prepay all of the debt outstanding under the loan agreement with LFRP Investors, L.P., an affiliate of HealthCare Royalty Partners, and for general corporate purposes.

  • Nova Measuring Instrument Ltd. delivers continuous innovation by providing advanced optical metrology solutions for the semiconductor manufacturing industry. Deployed with the world's largest integrated-circuit manufacturers, Nova's products deliver state-of-the-art, high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle. Nova's product portfolio, which combines high-precision hardware and cutting-edge software, supports the development and production of the most advanced devices in today's high-end semiconductor market. Nova's technical innovation and market leadership enable customers to improve process performance, enhance products' yields and accelerate time to market. Nova acts as a partner to semiconductor manufacturers from its offices around the world.

    Nova Measuring Instrument Ltd. (NASDAQ: NVMI) announced that it has completed the acquisition of ReVera Incorporated, a leading provider of materials metrology solutions for complex, multi-layer film stacks for advanced node semiconductor manufacturing for a net purchase price of $46.5 million in cash. Needham & Company acted as a financial advisor as part of its services. The synergy between Nova’s Optical CD technology and ReVera’s unique X-Ray Photoelectron Spectroscopy (XPS) technology will deliver leading edge solutions for superior process control at the most advanced technology nodes.

  • Kornit Digital Ltd. develops, designs and markets innovative digital printing solutions for the global printed textile industry. Kornit's solution includes its proprietary digital printing systems, ink and other consumables, associated software and value added services. Kornit's vision is to revolutionize the textile industry by facilitating the transition from analog processes that have not evolved for decades to digital methods of production that address contemporary supply, demand and environmental dynamics. Kornit is a global company headquartered in Rosh-Ha`Ayin, Israel, with U.S. offices in Mequon, Wisconsin and additional sales, support and marketing offices in Germany and Hong Kong.

    Kornit Digital Ltd. (NASDAQ: KRNT) raised $81.7 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,065,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Kornit Digital for general corporate purposes including working capital, to increase our visibility in the marketplace, to create a public market for our ordinary shares and to facilitate our future access to the public equity markets.

  • SolarEdge provides an intelligent inverter solution that has changed the way power is harvested and managed in solar photovoltaic systems. The SolarEdge DC optimized inverter system maximizes power generation at the individual PV module-level while lowering the cost of energy produced by the solar PV system. The SolarEdge system consists of power optimizers, inverters and a cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations.

    SolarEdge Technologies (NASDAQ: SEDG) raised $144.9 million in its initial public offering at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,050,000 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SolarEdge Technologies for general corporate purposes, including working capital and expansion of their business into additional markets.

  • BEEcube is a technology innovator and leading supplier of advanced all programmable real-time signal processing platforms used in communications, defense, education and research for real-time prototyping, academic research, military communications, surveillance/signal intelligence and advanced wireless research/5G and infrastructure deployment. BEEcube will operate as a wholly-owned NI subsidiary going forward.

    BEEcube, a technology innovator and leading supplier of high-performance FPGA prototyping and deployment products for advanced wireless research, completed its previously announced sale to National Instruments (NASDAQ: NATI)., the provider of platform-based systems that enable engineers and scientists to solve the world’s greatest engineering challenges. BEEcube will operate as a wholly-owned NI subsidiary. The terms of the transaction have not been publicly disclosed. Needham acted as financial advisor to BEEcube on this transaction.

  • Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

    Esperion Therapeutics, Inc. (NASDAQ: ESPR) raised $201.3 million in its follow-on offering at $100.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 262,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering as well as its other existing capital resources, will be used by Esperion Therapeutics, Inc. to complete the clinical development of ETC-1002, including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.

  • HubSpot is the world’s leading inbound marketing and sales platform. Since 2006, HubSpot has been on a mission to make the world more inbound. Today, over 12,000 customers in more than 75 countries use HubSpot’s software, services, and support to transform the way they attract, engage, and delight customers. HubSpot’s inbound marketing software, ranked #1 in customer satisfaction by VentureBeat and G2Crowd, includes social media publishing and monitoring, blogging, SEO, website content management, email marketing, marketing automation, and reporting and analytics, all in one integrated platform. Sidekick, HubSpot’s award-winning sales application, enables sales and service teams to have more effective conversations with leads, prospects, and customers. HubSpot is headquartered in Cambridge, MA with an office in Dublin, Ireland, and has been recognized by Inc., Forbes, and Deloitte as one of the world’s fastest-growing companies.

    HubSpot, Inc. (NYSE: HUBS) raised $175.1 million in its follow-on offering at $37.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 617,172 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by HubSpot, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

    Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $51.75 million in its follow-on offering at $8.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 818,181 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences primarily for preclinical and clinical development of our lead product candidates, discovery, research and development of other product candidates and other corporate purposes.

  • Mandalay Digital Group, Inc., through its wholly owned subsidiary, Digital Turbine, provides mobile solutions for wireless carriers globally to enable them to better monetize mobile content. The Company's products include mobile application management through DT Ignite, user experience and discovery through DT IQ, application stores and content through DT Marketplace, and content management and mobile payments through DT Pay. With global headquarters in Los Angeles, and offices in the U.S., Asia Pacific and EMEA, Mandalay Digital's solutions are used by more than 31 million consumers each month across more than 20 global operators.

    Mandalay Digital Group (Nasdaq:MNDL) announced that it has completed the acquisition of Appia, the leading independent mobile user acquisition network, in a stock-for-stock transaction. Appia shareholders received approximately 19 million shares of newly issued Digital Turbine stock, or approximately 33% of the combined company. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Mandalay Digital Group as part of its services.

  • Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially improve the competitive standing of these businesses and enhance their value for employees, customers and shareholders. Among Vector's notable investments are Aladdin Knowledge Systems, Allegro Development, Cambium Networks, Certara, CollabNet, Corel, IPVALUE Management, LANDesk Software, Niku, Gerber Scientific, RAE Systems, Register.com, Saba, SafeNet, Technicolor, Teletrac, Tidel, Triton Digital, WatchGuard Technologies and WinZip.

    Vector Capital announced that it has completed the acquisition of ChyronHego Corporation, a leading provider in broadcast graphics creation, play-out and real-time data visualization offering a wide variety of products and services for live television, news and sports production, for a net purchase price of $120 million in cash. Needham & Company acted as a financial advisor to Vector Capital on this transaction.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo™ for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite® for bacterial conjunctivitis and BromSite™ for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors. Nicox is headquartered in France.

    Nicox S.A. (Euronext Paris: COX) completed the pricing financing of 15 million shares at €1.80, for gross proceeds of approximately €27 million or $28.53 million through a private placement made to specific categories of investors. Needham acted as co-placement agent for this transaction. The net proceeds from the sale of the shares will be used by Nicox to provide additional resources to the Company to finance its strategy, in particular: *Working capital and general corporate purposes. *Clinical development and regulatory filings related to pipeline candidates. *Strengthening the Company’s commercial organization in Europe and the United States. *Listing of new shares.

  • MaxPoint provides a leading business intelligence and digital marketing solution that enables national brands to drive local, in-store sales. The company’s proprietary Digital Zip® technology and the MaxPoint Intelligence Platform predict the most likely local buyers of a specific product at a particular retail location and then execute cross-channel digital marketing campaigns to reach these buyers. MaxPoint has worked with each of the top 20 leading national advertisers and each of the top 10 advertising agencies in the United States as ranked by Advertising Age.

    MaxPoint Interactive, Inc. (NYSE: MXPT) raised $74.8 million in its initial public offering at $11.50 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by MaxPoint Interactive for general corporate purposes, including working capital, sales and marketing activities, engineering initiatives including enhancement of our solution, investment in technology and development and capital expenditures.

  • Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.

    Summit Therapeutics (NASDAQ: SMMT) raised $39.3 million in its initial public offering at $9.90 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 517,500 shares of common stock at the offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Summit Therapeutics for general corporate purposes including working capital, product development and operating expenses.

  • Q2 is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

    Q2 Holdings, Inc. (NYSE: QTWO) raised $116.34 million in its upsized follow-on offering at $19.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 768,352 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the Q2 Holdings for working capital and other general corporate purposes, including to finance their expected growth, develop new technologies, fund capital expenditures, or expand the company's existing business through investments in or acquisitions of other businesses or technologies.

  • Quintic is the supplier of QBlue, a world class Bluetooth Low Energy product line. Leveraging their expertise in ultra-low power and high performance RF IC design, Quintic is delivering leading wireless connectivity and control solutions for consumer electronics, wearable devices and their peripherals.

    Quintic Microelectronics completed its previously announced sale of its assets and IP related to its Wearable and Bluetooth Low Energy (BTLE) IC business to NXP semiconductors N.V. (NASDAQ: NXPI), creator of solutions that enable secure connections for a smarter world. The transaction contributes to NXP’s drive to create security and connectivity solutions for Internet-of-Things applications in Health & Fitness Wearables, Mobile Transactions, Proximity Marketing, Smart Home and Automotive. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Quintic on this transaction.

  • 3D Systems is pioneering 3D design and fabrication for everyone. 3DS provides the most advanced and comprehensive solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful ecosystem empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS' leading 3D healthcare solutions include end-to-end simulation, training and planning and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. Its democratized 3D digital design, fabrication and inspection products provide seamless interoperability between subtractive and additive manufacturing and incorporate the latest immersive computing technologies. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

    3D Systems (NYSE:DDD), is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike announced that it has completed the acquisition of Cimatron Ltd. (Nasdaq:CIMT), a leading provider of integrated CAD/CAM software solutions for the toolmaking and manufacturing industries for approximately $97 million, inclusive of Cimatron's net cash. Needham & Company served as exclusive financial advisor to 3D Systems on this transaction.

  • Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma.

    Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) raised $202.4 million in its follow-on offering at $176.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 150,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Intercept Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • Oerlikon is a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation. Based on these core competencies, Oerlikon develops production systems, components, and services for high-technology products. The company's commercial activities center on turn-key solutions for the manufacturing of protective coatings for precision tools and components (Surface Solutions Segment), systems for producing vacuums and conveying process gases (Vacuum Segment), equipment for textile production (Manmade Fibers Segment) and propulsion technology (Drive Systems Segment).

    OC Oerlikon Corporation AG (SIX: OERL), a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation, announced the successful closing of the sale of its Advanced Technologies Segment to Evatec AG, a customer-focused business which produces its thin-film deposition products to the highest standards. Both capital equipment businesses are well positioned in their respective markets by delivering complete thin film production solutions and services to their customers around the globe. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Oerlikon on this transaction.

  • BTU International, Inc. is global supplier and technology leader of advanced thermal processing equipment and processes to the electronics and alternative energy manufacturing markets. BTU equipment is used in the production of printed circuit board assemblies and semiconductor packaging as well as in solar cell and nuclear fuel manufacturing.

    BTU International, Inc. (NASDAQ: BTUI), a global supplier of advanced thermal processing equipment to the electronics and alternative energy manufacturing markets, completed its previously announced sale to Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers. Under the terms of the merger agreement, BTU shareholders received 0.3291 shares of Amtech common stock per share of BTU common stock. The transaction valued BTU at approximately $26.2 million based on Amtech’s close price on Friday, January 30, 2015. Needham & Company acted as exclusive financial advisor to BTU International on the transaction.

  • NeuLion, Inc. offers the true end-to-end solution for delivering live and on-demand content to Internet-enabled devices. NeuLion enables content owners and distributors, cable operators and telecommunications companies to capitalize on the massive consumer demand for viewing video content on PCs, smartphones, iPads and other similar devices. NeuLion's customers include major entertainment, sports, global content and news companies. NeuLion is based in Plainview, NY.

    NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, announced that it has completed the acquisition of DivX Corporation, a leading provider of next-generation digital video solutions. The total transaction value is approximately $62.5 million. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of NeuLion, Inc. as part of its services.

  • Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

    Omeros Corporation (NASDAQ: OMER) raised $84 million in its follow-on offering at $20.03 per share of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 449,325 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Omeros Corporation for general corporate purposes, including expenses related to the commercialization of Omidria™, research and development expenses, such as funding clinical trials, preclinical studies, manufacturing development and costs associated with otherwise advancing the company's drug candidates toward New Drug Application submission. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

  • TRACON Pharmaceuticals, Inc. develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

    TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) raised $36 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by TRACON Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

  • Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) raised $517.5 million in its follow-on offering at $95 per share. Needham acted as the co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 710,526 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Alnylam Pharmaceuticals for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020.

  • Sanbolic is an innovator and leader in workload-oriented storage virtualization technologies. Sanbolic technology enables customers to software-define storage to optimize the delivery of application-specific workloads, from any media type – SSD, Flash and hard drives in NAS, SAN, server-side and cloud deployments – improving storage load balancing, application availability and delivering the highest-performance end-user experience.

    Sanbolic, an innovator and leader in workload-oriented storage virtualization technologies, completed its previously announced sale to Citrix Systems, Inc. (NASDAQ: CTXS), a leader in mobile workspaces, providing virtualization, mobility management, networking and cloud services to enable new ways to work better. The terms of the acquisition were not disclosed. Needham & Company served as exclusive financial advisor to Sanbolic on this transaction.

Investment Banking